Swiss rare dis­ease biotech with­draws IPO to up­date its Nas­daq plans

Months af­ter it first went for a for­mal US list­ing, Re­lief Ther­a­peu­tics is with­draw­ing its IPO ap­pli­ca­tion in what the rare dis­ease play­er calls a change of plans.

Re­lief, which is on the SIX Swiss Ex­change, had filed an F-1 with the SEC back in Au­gust, propos­ing to of­fer Amer­i­can De­posi­tary Shares (ADS), which each rep­re­sent 150 of Re­lief’s or­di­nary shares in Switzer­land, on Nas­daq.

Un­der those plans, Re­lief aimed to raise about $25 mil­lion through a mix of ADS and war­rants to pur­chase its ADS.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER